{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:30:32Z","timestamp":1783002632305,"version":"3.54.5"},"reference-count":41,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals International AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: This study aimed to gain real-world insights from healthcare professionals (HCPs) regarding the management of adult patients with short bowel syndrome and intestinal failure (SBS-IF) who received teduglutide and achieved parenteral support (PS) independence or PS volume stability for \u226512 months. Methods: This cross-sectional survey was conducted in five European countries and Canada via a self-reported questionnaire (November 2022\u2013March 2023) among HCPs who manage patients with SBS-IF and who had prescribed teduglutide to \u22655 patients with SBS-IF receiving PS. Results: Of the 70 HCPs who completed the survey, almost all reported managing patients with SBS-IF who achieved PS independence or PS volume stability (99%, 69\/70 and 97%, 68\/70, respectively) and maintained the standard teduglutide dose, without changes. A total of 52 HCPs managed patients who achieved PS independence and discontinued teduglutide. Of these HCPs, 73% (38\/52) anticipated that these patients would remain PS-independent, not requiring PS reintroduction. Of the remainder, 79% (11\/14) estimated that \u226440% of these patients would require PS reintroduction. While many HCPs (81%, 42\/52) would reintroduce teduglutide in patients who discontinued its use after achieving PS independence, none would do so for patients who discontinued teduglutide after achieving PS volume stability if a patient\u2019s condition worsened. Conclusions: This survey found that patients with SBS-IF can achieve PS independence or PS volume stability with teduglutide treatment. However, some HCPs (27%, 14\/52) believe that a proportion of patients discontinuing teduglutide after achieving PS independence will require PS reintroduction. This survey suggests that teduglutide treatment should continue uninterrupted, unless clinically indicated, but this requires confirmation in future studies.<\/jats:p>","DOI":"10.3390\/nu16213762","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T09:49:14Z","timestamp":1730454554000},"page":"3762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6589-5712","authenticated-orcid":false,"given":"Felix","family":"Harpain","sequence":"first","affiliation":[{"name":"Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Milicevic","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, 8152 Glattpark, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0756-3415","authenticated-orcid":false,"given":"Lucy","family":"Howard","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington SK10 5JB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-3310","authenticated-orcid":false,"given":"Patricia","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, 8152 Glattpark, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-8348","authenticated-orcid":false,"given":"Ulrich-Frank","family":"Pape","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Charit\u00e9 Mitte and Campus Virchow-Klinikum, Charit\u00e9 Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"},{"name":"Department of Internal Medicine and Gastroenterology, Asklepios Klinik St. Georg, Asklepios Medical School, 20099 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bioletto, F., D\u2018Eusebio, C., Merlo, F.D., Aimasso, U., Ossola, M., Pellegrini, M., Ponzo, V., Chiarotto, A., De Francesco, A., and Ghigo, E. (2022). Efficacy of teduglutide for parenteral support reduction in patients with short bowel syndrome: A systematic review and meta-analysis. Nutrients, 14.","DOI":"10.3390\/nu14040796"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bl\u00fcthner, E., Pape, U.F., Tacke, F., and Greif, S. (2023). Quality of life in teduglutide-treated patients with short bowel syndrome intestinal failure-a nested matched pair real-world study. Nutrients, 15.","DOI":"10.3390\/nu15081949"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"B\u00fcttner, J., Bl\u00fcthner, E., Greif, S., K\u00fchl, A., Elezkurtaj, S., Ulrich, J., Maasberg, S., Jochum, C., Tacke, F., and Pape, U.F. (2023). Predictive potential of biomarkers of intestinal barrier function for therapeutic management with teduglutide in patients with short bowel syndrome. Nutrients, 15.","DOI":"10.3390\/nu15194220"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.clnu.2018.07.030","article-title":"Experience with teduglutide treatment for short bowel syndrome in clinical practice","volume":"38","author":"Pevny","year":"2019","journal-title":"Clin. Nutr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.clnu.2012.12.001","article-title":"Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL\u2122) scale","volume":"32","author":"Fragkos","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.clnu.2012.08.007","article-title":"Determinants of home parenteral nutrition dependence and survival of 268 patients with non-malignant short bowel syndrome","volume":"32","author":"Amiot","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0016-5085(99)70388-4","article-title":"Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome","volume":"117","author":"Messing","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jpen.1531","article-title":"Determinants of quality of life in patients with intestinal failure receiving long-term parenteral nutrition using the SF-36 questionnaire: A German single-center prospective observational study","volume":"44","author":"Bednarsch","year":"2020","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1016\/j.clnu.2021.02.009","article-title":"Quality of life in patients and in family members of those receiving home parenteral support with intestinal failure: A systematic review","volume":"40","author":"Sowerbutts","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/j.gastro.2012.09.007","article-title":"Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure","volume":"143","author":"Jeppesen","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/gut.2004.061440","article-title":"Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients","volume":"54","author":"Jeppesen","year":"2005","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0148607116680791","article-title":"Independence from parenteral nutrition and intravenous fluid support during treatment with teduglutide among patients with intestinal failure associated with short bowel syndrome","volume":"41","author":"Iyer","year":"2017","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1038\/ctg.2015.69","article-title":"Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome","volume":"7","author":"Schwartz","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ncp.10092","article-title":"Reduction of parenteral nutrition and hydration support and safety with long-term teduglutide treatment in patients with short bowel syndrome-associated intestinal failure: STEPS-3 study","volume":"33","author":"Seidner","year":"2018","journal-title":"Nutr. Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1756283X11436318","article-title":"Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome","volume":"5","author":"Jeppesen","year":"2012","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_17","unstructured":"Electronic Medicines Compendium (2023, November 10). Revestive (Teduglutide). Summary of Product Characteristics. Takeda. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/3382\/smpc."},{"key":"ref_18","unstructured":"Therapeutic Goods Administration, TGA (2024, February 16). Revestive, Available online: https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2017-PI-01864-1&d=20231129172310101."},{"key":"ref_19","unstructured":"(2024, October 28). Revestive\u00ae [Package Insert]; Takeda Pharmaceutical Company Limited: Tokyo, Japan. Available online: https:\/\/www.rad-ar.or.jp\/siori\/english\/search\/result?n=45061."},{"key":"ref_20","unstructured":"Food and Drug Administration, FDA (2024, February 16). GATTEX\u00ae (Teduglutide), Available online: https:\/\/www.shirecontent.com\/PI\/PDFS\/Gattex_USA_ENG.pdf."},{"key":"ref_21","unstructured":"Canada\u2019s Drug and Health Technology Agency (2024, April 19). Revestive. Canadian Drug Expert Committee Final Recommendation, Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0459_Revestive_complete_Jul-29_16.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1016\/j.clnu.2019.12.019","article-title":"Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study","volume":"39","author":"Joly","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/0148607115594010","article-title":"Clinical management of patients with parenteral nutrition-dependent short bowel syndrome during teduglutide therapy","volume":"40","author":"Compher","year":"2016","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.clnesp.2022.08.027","article-title":"Long-term results of teduglutide treatment for chronic intestinal failure\u2014Insights from a national, multi-centric patient home-care service program","volume":"51","author":"Greif","year":"2022","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MCG.0000000000000604","article-title":"Safety and efficacy of teduglutide (Gattex) in patients with Crohn\u2019s disease and need for parenteral support due to short bowel syndrome-associated intestinal failure","volume":"51","author":"Kochar","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jpen.1011","article-title":"Single-center experience with the use of teduglutide in adult patients with short bowel syndrome","volume":"42","author":"Lam","year":"2018","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/jpen.1838","article-title":"Long-term outcomes with teduglutide from a single center","volume":"45","author":"Puello","year":"2021","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/jpen.1149","article-title":"Long-term therapy with teduglutide in parenteral support-dependent patients with short bowel syndrome: A case series","volume":"42","author":"Ukleja","year":"2018","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/jpen.2272","article-title":"Teduglutide in short bowel syndrome patients: A way back to normal life?","volume":"46","author":"Harpain","year":"2022","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1756284818793343","DOI":"10.1177\/1756284818793343","article-title":"GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting","volume":"11","author":"Schoeler","year":"2018","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"de Dreuille, B., Nuzzo, A., Bataille, J., Mailhat, C., Billiauws, L., Le Gall, M., and Joly, F. (2023). Post-marketing use of teduglutide in a large cohort of adults with short bowel syndrome-associated chronic intestinal failure: Evolution and outcomes. Nutrients, 15.","DOI":"10.3390\/nu15112448"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0148607113512678","article-title":"Short bowel syndrome: Highlights of patient management, quality of life, and survival","volume":"38","author":"Kelly","year":"2014","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ncp.11015","article-title":"Use of teduglutide in adults with short bowel syndrome-associated intestinal failure","volume":"39","author":"Pironi","year":"2024","journal-title":"Nutr. Clin. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Solar, H., Ortega, M.L., and Gondolesi, G. (2024). Current status of chronic intestinal failure management in adults. Nutrients, 16.","DOI":"10.3390\/nu16162648"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.clnu.2023.07.019","article-title":"ESPEN guideline on chronic intestinal failure in adults\u2014Update 2023","volume":"42","author":"Pironi","year":"2023","journal-title":"Clin. Nutr."},{"key":"ref_36","unstructured":"FDA (2024, February 16). Code of Federal Regulations. Food and Drugs. Exemptions from IRB Requirement (56.104), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=56.104."},{"key":"ref_37","unstructured":"FDA (2024, February 16). Code of Federal Regulations. Public Welfare (Exempt Research: 46.104), Available online: https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-A\/part-46\/subpart-A\/section-46.104."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1053\/j.gastro.2005.09.068","article-title":"Glucagon-like peptide-2: Update of the recent clinical trials","volume":"130","author":"Jeppesen","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.nut.2016.12.022","article-title":"The Polish Intestinal Failure Centres\u2019 consensus on the use of teduglutide for the treatment of short bowel syndrome","volume":"38","author":"Klek","year":"2017","journal-title":"Nutrition"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zaczek, Z., Jurczak-Kobus, P., Panczyk, M., Braszczy\u0144ska-Sochacka, J., Majewska, K., Kunecki, M., D\u0105browska, K., and Sobocki, J. (2022). Changes in parenteral nutrition requirements and BMI in patients with parenteral nutrition-dependent short bowel syndrome after stopping teduglutide-9 years of follow-up. Nutrients, 14.","DOI":"10.3390\/nu14081634"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wauters, L., Dermine, S., de Dreuille, B., Bettolo, J., Hutinet, C., Mohamed, A., Lecoq, E., Billiauws, L., Nuzzo, A., and Corcos, O. (2023). Malnutrition with low muscle mass is common after weaning off home parenteral nutrition for chronic intestinal failure. Nutrients, 15.","DOI":"10.3390\/nu15020338"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/21\/3762\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:26:45Z","timestamp":1760113605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/21\/3762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":41,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["nu16213762"],"URL":"https:\/\/doi.org\/10.3390\/nu16213762","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}